Scopus BioPharma develops treatments for serious diseases using transformative therapeutics. Their focus is on immuno-oncology gene therapy for various cancers, and they have developed a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors and MRI-1867, a dual-action, hybrid, and small molecule drug. Partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem have been established to support the development and other programs.